ResMed (RMD) Issues Quarterly Earnings Results

ResMed (NYSE:RMD) posted its quarterly earnings results on Monday. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.22, Bloomberg Earnings reports. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The business had revenue of $601.27 million during the quarter, compared to analyst estimates of $583.77 million. During the same period in the prior year, the business posted $0.73 earnings per share. The company’s revenue was up 13.4% on a year-over-year basis.

ResMed (NYSE:RMD) traded down $1.17 during trading on Monday, hitting $87.51. 1,087,658 shares of the stock were exchanged, compared to its average volume of 518,377. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $12,584.04, a price-to-earnings ratio of 35.43, a P/E/G ratio of 2.24 and a beta of 0.79. ResMed has a one year low of $62.64 and a one year high of $89.72.

Several research firms have issued reports on RMD. Zacks Investment Research lowered shares of ResMed from a “buy” rating to a “hold” rating in a research report on Friday. BMO Capital Markets upped their price target on shares of ResMed to $82.00 and gave the company a “market perform” rating in a research report on Tuesday, December 12th. JPMorgan Chase & Co. upped their price target on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a research report on Monday, October 30th. Barclays upped their price target on shares of ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Finally, Northland Securities restated a “sell” rating and set a $55.00 price target on shares of ResMed in a research report on Friday, October 27th. Four analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. ResMed presently has an average rating of “Hold” and a consensus price target of $70.57.

In other news, insider James Hollingshead sold 600 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total transaction of $50,976.00. Following the completion of the sale, the insider now directly owns 62,602 shares in the company, valued at $5,318,665.92. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 118,392 shares of the stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $82.70, for a total transaction of $9,791,018.40. Following the completion of the transaction, the director now directly owns 306,615 shares of the company’s stock, valued at $25,357,060.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 158,929 shares of company stock valued at $13,181,009. 1.77% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “ResMed (RMD) Issues Quarterly Earnings Results” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/22/resmed-rmd-issues-quarterly-earnings-results.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit